The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 601–700 of 1,158
Giacomucci, G., Mazzeo, S., Bagnoli, S., Ingannato, A., Leccese, D., Berti, V., Padiglioni, S., Galdo, G., Ferrari, C., Sorbi, S., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11055-5 · Cited by 156
Animal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155
FDG-PET as an independent biomarker for Alzheimer’s biological diagnosis: A longitudinal study
Initiative, O. B. O. A. D. N., Ou, Y.-N., Xu, W., Li, J.-Q., Guo, Y., Cui, M., Chen, K.-L., Huang, Y.-Y., Dong, Q., Tan, L., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0512-1 · Cited by 155
Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
Risacher, S. L., & Saykin, A. J. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359312 · Cited by 155
Alber, J., Goldfarb, D., Thompson, L. I., Arthur, E., Hernandez, K., Cheng, D., DeBuc, D. C., Cordeiro, F., Provetti‐Cunha, L., den Haan, J., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12006 · Cited by 154
Challenges of multimorbidity of the aging brain: a critical update
Jellinger, K. A., & Attems, J. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1288-x · Cited by 154
Diagnosing Mild Cognitive Impairment (MCI) in clinical trials: a systematic review
Stephan, B. C. M., Minett, T., Pagett, E., Siervo, M., Brayne, C., & McKeith, I. G. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001909 · Cited by 154
Relationship Between DTI Metrics and Cognitive Function in Alzheimer’s Disease
Mayo, C. D., García-Barrera, M. A., Mazerolle, E. L., Ritchie, L. J., Fisk, J. D., Gawryluk, J. R., & Initiative, A. D. N. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00436 · Cited by 154
Cerebrospinal Fluid Biomarker for Alzheimer Disease Predicts Postoperative Cognitive Dysfunction
Evered, L. A., SILBERT, B. S., Scott, D. A., Ames, D. J., Maruff, P. T., & Blennow, K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000953 · Cited by 153
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Chen, Y., Wang, Y., Song, Z., Fan, Y., Gao, T., & Tang, X. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101911 · Cited by 152
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects
Lim, H. K., Nebes, R. D., Snitz, B. E., Cohen, A. D., Mathis, C. A., Price, J. C., Weissfeld, L. A., Klunk, W. E., & Aizenstein, H. J. (2014) · Brain · doi:10.1093/brain/awu271 · Cited by 152
Eyler, L. T., Elman, J. A., Hatton, S. N., Gough, S., Mischel, A. K., Hagler, D. J., Franz, C. E., Docherty, A. R., Fennema‐Notestine, C., Gillespie, N. A., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180847 · Cited by 152
Wirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4409-12.2013 · Cited by 151
Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
Nakamura, A., Cuesta, P., Fernández, A., Arahata, Y., Iwata, K., Kuratsubo, I., Bundo, M., Hattori, H., Sakurai, T., Fukuda, K., et al. (2018) · Brain · doi:10.1093/brain/awy044 · Cited by 151
Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy
Ossenkoppele, R., Schonhaut, D. R., Baker, S. L., O’Neil, J. P., Janabi, M., Ghosh, P. M., Santos‐Santos, M., Miller, Z., Bettcher, B. M., Gorno‐Tempini, M. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24321 · Cited by 151
Mormino, E. C., Brandel, M. G., Madison, C. M., Marks, S. M., Baker, S. L., & Jagust, W. J. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr255 · Cited by 151
Sex differences in episodic memory in early midlife: impact of reproductive aging
Rentz, D. M., Weiss, B. K., Jacobs, E. G., Cherkerzian, S., Klibanski, A., Remington, A., Aizley, H. G., & Goldstein, J. M. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000771 · Cited by 151
Grothe, M. J., Teipel, S. J., & Initiative, F. T. A. D. N. (2016) · Human Brain Mapping · doi:10.1002/hbm.23018 · Cited by 150
Statins, cognition, and dementia-systematic review and methodological commentary
Power, M. C., Weuve, J., Sharrett, A. R., Blacker, D., & Gottesman, R. F. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.35 · Cited by 150
Cheng, Y.-W., Chen, T.-F., & Chiu, M.-J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s123428 · Cited by 150
Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Staff, N. P., Jones, D. T., & Singer, W. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.001 · Cited by 150
Incidence of cerebral microbleeds in preclinical Alzheimer disease
Yates, P. A., Desmond, P. M., Phal, P. M., Steward, C., Szoeke, C., Salvado, O., Ellis, K. A., Martins, R. N., Masters, C. L., Ames, D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000285 · Cited by 150
Self-citationHerskowitz, J. H., Feng, Y., Mattheyses, A. L., Hales, C. M., Higginbotham, L. A., Duong, D. M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Seyfried, N. T., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2508-13.2013 · Cited by 150
Self-citationLim, Y. Y., Ellis, K. A., Harrington, K., Ames, D. J., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G. R., Szoeke, C. E. I., Darby, D., et al. (2012) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2011.643227 · Cited by 150
Self-citationJak, A. J., Preis, S. R., Beiser, A., Seshadri, S. S., Wolf, P. A., Bondi, M. W., & Au, R. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000199 · Cited by 150
Association of midlife lipids with 20‐year cognitive change: A cohort study
Power, M. C., Rawlings, A. M., Sharrett, A. R., Bandeen‐Roche, K., Coresh, J., Ballantyne, C. M., Pokharel, Y., Michos, E. D., Penman, A. D., Alonso, Á., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.07.757 · Cited by 151
Ushering in the study and treatment of preclinical Alzheimer disease
Langbaum, J. B. S., Fleisher, A., Chen, K., Ayutyanont, N., Lopera, F. J., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 149
Self-citationBonanni, L., Perfetti, B., Bifolchetti, S., Taylor, J., Franciotti, R., Parnetti, L., Thomas, A., & ONOFRJ, M. C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.009 · Cited by 150
Fletcher, E. M., Raman, M. R., Huebner, P. A., Liu, A., Mungas, D., Carmichael, O. T., & DeCarli, C. S. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3263 · Cited by 149
Mediterranean diet and preserved brain structural connectivity in older subjects
Pelletier, A., Barul, C., Féart, C., Helmer, C., Bernard, C., Periot, O., Dilharreguy, B., Dartigues, J., Michèle Allard, A., Barberger‐Gateau, P., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1888 · Cited by 149
Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels
Babulal, G. M., Ghoshal, N., Head, D. M., Vernon, E. K., Holtzman, D. M., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., & Roe, C. M. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.04.004 · Cited by 149
Self-citationLöwe, L. C., Gaser, C., Franke, K., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157514 · Cited by 149
Gouw, A. A., Alsema, A. M., Tijms, B. M., Borta, A., Scheltens, P., Stam, C. J., & van der Flier, W. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.017 · Cited by 149
Gupta, V. B., Chitranshi, N., den Haan, J., Mirzaei, M., You, Y., Lim, J. K. H., Basavarajappa, D. K., Godinez, A., Angelantonio, S. D., Sachdev, P. S., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100899 · Cited by 149
Mixed dementia: A review of the evidence
Custodio, N., Montesinos, R., Lira, D., Herrera-Pérez, E., Bardales, Y., & Valeriano-Lorenzo, L. (2017) · Dementia & Neuropsychologia · doi:10.1590/1980-57642016dn11-040005 · Cited by 148
Panza, F., Solfrizzi, V., Barulli, M. R., Santamato, A., Seripa, D., Pilotto, A., & Logroscino, G. (2015) · Rejuvenation Research · doi:10.1089/rej.2014.1637 · Cited by 148
Braak, H., Zetterberg, H., Tredici, K. D., & Blennow, K. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1139-0 · Cited by 148
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 148
Self-citationZhang, M., Cheng, Q., Zheng, Z., Qian, F., Wang, Y., Thu, P. M., Zhang, X., Zhou, Y., Tu, L., Liu, Q., et al. (2018) · Theranostics · doi:10.7150/thno.26164 · Cited by 148
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147
Self-citationWolk (2012) · doi:10.1097/wco.0b013e328354ff0a · Cited by 147
Ryzhikova, E., Kazakov, O., Halámková, L., Celmins, D. F., Malone, P., Molho, E., Zimmerman, E. A., & Lednev, I. K. (2014) · Journal of Biophotonics · doi:10.1002/jbio.201400060 · Cited by 147
Pupillary Responses as a Biomarker of Early Risk for Alzheimer’s Disease
Granholm, E. L., Panizzon, M. S., Elman, J. A., Jak, A. J., Hauger, R. L., Bondi, M. W., Lyons, M. J., Franz, C. E., & Kremen, W. S. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161078 · Cited by 147
Liu, X., Chen, K., Wu, T., Weidman, D. A., Lure, F. Y. M., & Li, J. (2018) · Translational research · doi:10.1016/j.trsl.2018.01.001 · Cited by 147
Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease
Liccardo, D., Marzano, F., Carraturo, F., Guida, M., Femminella, G. D., Bencivenga, L., Agrimi, J., Addonizio, A., Melino, I., Valletta, A., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00683 · Cited by 148
Diagnosis of Alzheimer's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera
Nagele, E. P., Han, M. C., DeMarshall, C. A., Belinka, B. A., & Nagele, R. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023112 · Cited by 147
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 146
Maruszak, A., & Thuret, S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00095 · Cited by 147
Alzheimer's Disease: A Clinical and Basic Science Review
Korolev, I. O. (2014) · Cited by 146
Alpha-2 macroglobulin in Alzheimer’s disease: a marker of neuronal injury through the RCAN1 pathway
Varma, V. R., Varma, S., An, Y., Hohman, T. J., Seddighi, S., Casanova, R., Beri, A., Dammer, E. B., Seyfried, N. T., Pletniková, O., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.206 · Cited by 146
Calderón‐Garcidueñas, L., González-Maciel, A., Reynoso-Robles, R., Delgado‐Chávez, R., Mukherjee, P. S., Kulesza, R. J., Torres‐Jardón, R., Ávila-Ramírez, J., & Villarreal-Ríos, R. (2018) · Environmental Research · doi:10.1016/j.envres.2018.03.023 · Cited by 146
Zhang, Y. S., Zhou, N., Knoll, B., Samra, S., Ward, M., Weıntraub, S., & Fawzi, A. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214685 · Cited by 146
Prediction of Alzheimer’s disease using blood gene expression data
Lee, T., & Lee, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-60595-1 · Cited by 146
Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Ijaz, H. W., Wang, W., & Lang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207660 · Cited by 146
The role of astrocytes in amyloid β-protein toxicity and clearance
Thal, D. R. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.04.021 · Cited by 146
Zhao, W., Wang, X., Yin, C., He, M., Li, S., & Han, Y. (2019) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2019.00013 · Cited by 145
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Self-citationAbsence of practice effects in preclinical Alzheimer’s disease.
Hassenstab, J. J., Ruvolo, D., Jasielec, M. S., Xiong, C., Grant, E., & Morris, J. C. (2015) · Neuropsychology · doi:10.1037/neu0000208 · Cited by 145
Functional network integrity presages cognitive decline in preclinical Alzheimer disease
Buckley, R. F., Schultz, A. P., Hedden, T., Papp, K. V., Hanseeuw, B. J., Marshall, G. A., Sepulcre, J., Smith, E. E., Rentz, D. M., Johnson, K. A., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004059 · Cited by 145
Self-citationBinary Classification of Alzheimer’s Disease Using sMRI Imaging Modality and Deep Learning
Tufail, A. B., Ma, Y.-K., & Zhang, Q.-N. (2020) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-019-00265-5 · Cited by 145
Smith, J. C., Nielson, K. A., Antuono, P., Lyons, J.-A., Hanson, R. J., Butts, A. M., Hantke, N. C., & Verber, M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130467 · Cited by 144
Chiu, M., Chen, Y., Chen, T., Yang, S., Yang, F., Tseng, T.-W., Chieh, J.-J., Chen, J.-C. R., Tzen, K., Hua, M., et al. (2013) · Human Brain Mapping · doi:10.1002/hbm.22390 · Cited by 144
Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 144
Yuki, D., Sugiura, Y., Zaima, N., Akatsu, H., Takei, S., Yao, I., Maesako, M., Kinoshita, A., Yamamoto, T., Kon, R., et al. (2014) · Scientific Reports · doi:10.1038/srep07130 · Cited by 144
A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults
Taylor, M. K., Sullivan, D. K., Swerdlow, R. H., Vidoni, E. D., Morris, J. K., Mahnken, J. D., & Burns, J. M. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.162263 · Cited by 145
Overview of Transgenic Mouse Models for Alzheimer's Disease
Myers, A., & McGonigle, P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.81 · Cited by 148
Zhou, Y., Chen, Y., He, H., Peng, M., Zeng, M., & Sun, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109690 · Cited by 147
Preclinical AD predicts decline in memory and executive functions in subjective complaints
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143
Cognitive impairment and BDNF serum levels
Siuda, J. S., Patalong‐Ogiewa, M., Żmuda, W., Targosz-Gajniak, M., Niewiadomska, E., Matuszek, I., Jędrzejowska–Szypułka, H., & Rudzińska, M. (2016) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2016.10.001 · Cited by 142
Cronin, P., McCarthy, M. J., Lim, A. S. P., Salmon, D. P., Galasko, D. R., Masliah, E., Jager, P. L. D., Bennett, D. A., & Desplats, P. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.003 · Cited by 143
Self-citationKnopman, D. S., Haeberlein, S. B., Carrillo, M. C., Hendrix, J. A., Kerchner, G., Margolin, R. A., Maruff, P. T., Miller, D. S., Tong, G., Tome, M. B., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.002 · Cited by 144
Self-citationCordone, S., Annarumma, L., Rossini, P. M., & Gennaro, L. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00695 · Cited by 143
Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration
Thomas, K. R., Bangen, K. J., Weigand, A. J., Edmonds, E. C., Wong, C. G., Cooper, S., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008838 · Cited by 144
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression
Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C., Wall, A. E., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001209 · Cited by 142
Self-citationTalbot, K., & Wang, H.-Y. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.007 · Cited by 142
Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 142
Zhang, H., Chen, X., Shi, F., Li, G., Kim, M., Giannakopoulos, P., Haller, S., & Shen, D. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160092 · Cited by 142
McNamara, R. K., Kalt, W., Shidler, M. D., McDonald, J. E., Summer, S. S., Stein, A. L., Stover, A. N., & Krikorian, R. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.003 · Cited by 142
Iwatsubo, T., Iwata, A., Suzuki, K., Ihara, R., Arai, H., Ishii, K., Senda, M., Ito, K., Ikeuchi, T., Kuwano, R., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.03.009 · Cited by 142
Self-citationCurrent and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo-Mínguez, Á., Kenigsberg, P.-A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P. H., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 142
Besson, F. L., La Joie, R., Doeuvre, L., Gaubert, M., Mezenge, F., Egret, S., Landeau, B., Barre, L., Abbas, A., Ibazizene, M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0150-15.2015 · Cited by 141
Brain Insulin Resistance in Alzheimer's Disease and its Potential Treatment with GLP-1 Analogs
Talbot, K. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.73 · Cited by 141
Snitz, B. E., Weissfeld, L. A., Cohen, A. D., Lopez, O. L., Nebes, R. D., Aizenstein, H. J., McDade, E., Price, J. C., Mathis, C. A., & Klunk, W. E. (2015) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.01.008 · Cited by 140
Neuroinflammation in Alzheimer’s Disease
Reinisch, V. M., Krause, D., & Müller, N. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1071-7_9 · Cited by 140
Fortea, J., Vilaplana, E., Alcolea, D. A., Carmona‐Iragui, M., Sánchez‐Saudinós, M., Sala, I., Antón‐Aguirre, S., González‐Ortiz, S., Medrano, S., Pegueroles, J., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24186 · Cited by 140
Harkins, K. A., Sankar, P. L., Sperling, R. A., Grill, J. D., Green, R. C., Johnson, K. A., Healy, M. E., & Karlawish, J. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0112-7 · Cited by 140
Self-citationRoshanzamir, A., Aghajan, H. K., & Baghshah, M. S. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01456-3 · Cited by 140
Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease
Karlawish, J. H. (2011) · Neurology · doi:10.1212/wnl.0b013e318232ac1a · Cited by 140
Brain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 139
Self-citationAmyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S. S., Sperling, R. A., Dale, A. M., & Initiative, A. D. N. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 139
Self-citationAwasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.01.008 · Cited by 139
Novel Cognitive Paradigms for the Detection of Memory Impairment in Preclinical Alzheimer’s Disease
Loewenstein, D., Curiel, R. E., Duara, R., & Herman Buschke, L. (2017) · Assessment · doi:10.1177/1073191117691608 · Cited by 139
The multiple sclerosis prodrome
Makhani, N., & Tremlett, H. L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00519-3 · Cited by 141
Köbe, T., Witte, A. V., Schnelle, A., Lesemann, A., Fabian, S., Tesky, V. A., Pantel, J., & Flöel, A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.09.050 · Cited by 138
The critical need for defining preclinical biomarkers in Alzheimer's disease
Fiandaca, M. S., Mapstone, M. E., Cheema, A. K., & Federoff, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.015 · Cited by 138
Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease
Ewers, M., Insel, P. S., Stern, Y., Weiner, M. W., & Initiative, A. D. N. (2013) · Neurology · doi:10.1212/wnl.0b013e31828970c2 · Cited by 138
Self-citationBasak, C., Qin, S., & O'Connell, M. A. (2020) · Psychology and Aging · doi:10.1037/pag0000442 · Cited by 138
Gauthier, S., Patterson, C., Chertkow, H., Gordon, M., Herrmann, N., Rockwood, K., Rosa-Neto, P., & Soucy, J.-P. (2012) · Canadian Geriatrics Journal · doi:10.5770/cgj.15.49 · Cited by 137
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
